CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 102 enrolled
Drug / intervention
PG-102(MG12) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06309667
NCT06309667Phase 1Completed
CompareCT.gov

A Double-blind, Randomized, Placebo Controlled, Combined Single (Part A) and Multiple (Part B, C) Ascending Dose, Phase 1 Study to Investigate the Safety, Tolerability and Pharmacokinetic and Pharmacodynamics Following Subcutaneous Injections of PG-102(MG12) in Healthy Adult and Obesity Participants

ProGen. Co., Ltd.·interventional·Posted Mar 13, 2024·Updated May 6, 2025

In Brief

A Phase 1 clinical trial evaluating PG-102(MG12) and Placebo for Healthy and Overweight. Completed, enrolled 102 participants across 1 site.

Detailed Summary

This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B, C) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and pharmacodynamics following subcutaneous injections of PG-102(MG12) in healthy adult participants. This study will be conducted in 3 Parts (Part A, B and C), with up to 5 cohorts in each part.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Overweight
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedMar 13, 2024
Enrollment StartMar 4, 2024
Primary CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.3 years ago

Interventions

PG-102(MG12)drug

GLP-1 and GLP-2 fusion protein

Placeboother

Placebo drug of PG-102(MG12)